菲利普莫里斯国际公司宣布，其加热不燃烧烟草设备Iqos已获得美国食品和药物管理局（FDA）的重新授权，继续作为改良风险烟草产品（MRTP）在市场销售。这一决定确认了Iqos相对于传统卷烟能够减少有害或潜在有害化学物质的暴露。
此次授权延续了该产品在美国市场的特殊地位，意味着菲利普莫里斯可以在营销中宣传Iqos作为传统卷烟的替代品，其产生的气溶胶含有较低水平的特定有害成分。FDA的重新授权基于对科学证据的持续审查，维护了最初授予该产品的改良风险认定。
对于菲利普莫里斯国际而言，这一监管里程碑巩固了Iqos在减害产品领域的战略定位，并支持公司向无烟未来转型的长期目标。该授权预计将为Iqos产品在美国市场的持续推广提供监管确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.